OL
OLMA.US Olema Pharmaceuticals Inc
- Market cap
- USD 662M
- P/E
- -
- P/B
- 1.79x
- ROE
- -68.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is OLMA.US undervalued?
Graham numberThe Graham number of Olema Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Olema Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Olema Pharmaceuticals Inc yet.
Olema Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Olema Pharmaceuticals Inc
Olema Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for breast cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal …
Full company profileOlema Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Olema Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -8.24K | -9.03K | -11.0K | -1.66M | -1.66M | -377K | -393K | - | - |
| Operating Income | -2.08M | -4.32M | -21.5M | -71.5M | -107M | -105M | -142M | -179M | -270M |
| EBITDA | -2.07M | -4.31M | -21.5M | -70.9M | -107M | -96.3M | -129M | -162M | -258M |
| Net Income | -2.20M | -4.32M | -22.1M | -71.1M | -103M | -96.7M | -129M | -162M | -253M |
| EPS | -0.16 | -0.11 | -0.56 | -1.80 | -2.56 | -2.14 | -2.20 | -1.87 | -2.50 |
| Balance Sheet | |||||||||
| Total Assets | 3.27M | 132K | 343M | 296M | 216M | 277M | 451M | 533M | 441M |
| Total Liabilities | 9.55M | 10.7M | 4.59M | 11.4M | 18.1M | 23.1M | 42.0M | 54.9M | 72.2M |
| Shareholders' Equity | -6.28M | -10.6M | 338M | 285M | 198M | 254M | 409M | 479M | 369M |
| Cash & Short-term Investments | 3.15M | 68.0K | 339M | 287M | 204M | 262M | 434M | 505M | 414M |
| Total Debt | - | - | - | 3.29M | 2.57M | 2.42M | 1.43M | 1.19M | 3.36M |
| Cash Flow | |||||||||
| Operating Cash Flow | -2.18M | -3.08M | -19.9M | -50.7M | -82.1M | -83.7M | -104M | -147M | -185M |
| Capital Expenditure | 56.0K | 56.0K | 56.0K | 1.58M | 363K | 0.00 | 159K | 0.00 | 1.20M |
| Free Cash Flow | -2.23M | -3.14M | -19.9M | -52.3M | -82.4M | -83.7M | -105M | -147M | -187M |
| Ratios | |||||||||
| ROE | - | - | -6.5% | -25.0% | -51.9% | -38.1% | -31.7% | -33.9% | -68.6% |
| ROA | -67.2% | -3,269.7% | -6.5% | -24.0% | -47.6% | -34.9% | -28.7% | -30.5% | -57.4% |
| Debt to Equity | - | - | - | 0.01x | 0.01x | 0.01x | 0.00x | 0.00x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Olema Pharmaceuticals Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 3.09M | 0.08 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Olema Pharmaceuticals Inc
- Insiders 2.09%
- Institutions 97.92%
- Public & others 0.00%
- Shares outstanding 87.6M
- Free float 59.3M
Top funds holding OLMA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 2.61M | 2.98% | 0.00% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 2.30M | 2.63% | +2.69% | Oct 2026 |
| iShares Russell 2000 ETF | 1.98M | 2.26% | 0.00% | Oct 2026 |
| Fidelity Select Health Care | 1.68M | 1.92% | 0.00% | Aug 2026 |
| Strategic Advisers Fidelity US TtlStk | 1.64M | 1.88% | +0.04% | Sep 2026 |
| Franklin Biotechnology Discv A(acc)USD | 1.00M | 1.15% | 0.00% | Sep 2026 |
| Janus Henderson Hrzn Biotec E2 USD | 874K | 1.00% | -0.37% | Jun 2026 |
| Fidelity Small Cap Index | 859K | 0.98% | +0.29% | Aug 2026 |
| Fidelity Advisor Health Care I | 820K | 0.94% | 0.00% | Sep 2026 |
| Columbia Small Cap Value Discv A | 793K | 0.91% | +44.50% | Sep 2026 |
| Fidelity Advisor Biotechnology I | 777K | 0.89% | 0.00% | Sep 2026 |
| Franklin Small Cap Growth Adv | 694K | 0.79% | 0.00% | Sep 2026 |
| Belfius Equities Cure C Cap | 671K | 0.77% | 0.00% | Apr 2026 |
| Janus Global Life Science AUSD | 652K | 0.75% | +2.86% | Sep 2026 |
| Janus Henderson Glb Life Scn I2 USD | 640K | 0.73% | +1.25% | Aug 2026 |
| Fidelity Select Biotechnology | 628K | 0.72% | 0.00% | Aug 2026 |
| iShares Russell 2000 Value ETF | 612K | 0.70% | 0.00% | Oct 2026 |
| Franklin Biotechnology Discovery A | 569K | 0.65% | 0.00% | Sep 2026 |
| iShares Biotechnology ETF | 548K | 0.63% | -0.19% | Oct 2026 |
| Fidelity Small Cap Discovery | 499K | 0.57% | +1.86% | Aug 2026 |
Top institutions holding OLMA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 12.1M | 13.87% | +16.91% | Jun 2026 |
| Paradigm Biocapital Advisors LP | 8.67M | 9.90% | +8.10% | Jun 2026 |
| Jupiter Topco LLC | 7.09M | 8.10% | 0.00% | Jun 2026 |
| Bain Capital Life Sciences Investors, LLC | 7.09M | 8.09% | -5.19% | Jun 2026 |
| BlackRock Inc | 6.71M | 7.67% | +18.80% | Jun 2026 |
| Bvf Inc | 5.30M | 6.05% | 0.00% | Jun 2026 |
| Siren, L.L.C. | 4.86M | 5.55% | +2.10% | Jun 2026 |
| State Street Corp | 4.32M | 4.93% | +9.61% | Jun 2026 |
| Vanguard Capital Management, LLC | 3.34M | 3.82% | +8.36% | Jun 2026 |
| Logos Global Management LP | 3.21M | 3.67% | 0.00% | Jun 2026 |
| Franklin Templeton Inc | 2.35M | 2.68% | +92.75% | Jun 2026 |
| Cormorant Asset Management, LLC | 2.15M | 2.46% | -44.87% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.83M | 2.09% | +50.72% | Jun 2026 |
| Geode Capital Management, LLC | 1.82M | 2.08% | +17.78% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 1.66M | 1.90% | +180.46% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.57M | 1.79% | +49.96% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 1.55M | 1.77% | +9.62% | Sep 2026 |
| Deep Track Capital, LP | 1.50M | 1.71% | 0.00% | Jun 2026 |
| Lightspeed Management Co LLC | 1.36M | 1.55% | 0.00% | Jun 2026 |
| Kingdon Capital Management LLC | 1.20M | 1.37% | +40.35% | Jun 2026 |
Olema Pharmaceuticals Inc company profile
- Company name
- Olema Pharmaceuticals Inc
- Ticker
- OLMA.US
- Exchange
- USA Stocks
- Listed since
- Nov 19, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 131
- Fiscal year end
- December
- Address
- 365 Oyster Point Blvd., South San Francisco, CA, United States, 94080
- Phone
- 415 651 3316
- Website
- olema.com
About Olema Pharmaceuticals Inc
Olema Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for breast cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer. It also develops OP-3136, an orally available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers. The company was formerly known as Olema Pharmaceuticals, Inc. and changed its name to Olema Oncology, Inc. in November 2026. Olema Oncology, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Olema Pharmaceuticals Inc management
9- Ms. Shawnte M. Mitchell J.D.Chief Legal Officer & Corporate Secretary · born 1978
- Ms. Courtney O'KonekVice President of Corporate Communications
- Ms. Julie DexterSenior VP & Head of People
- Dr. Naseem Zojwalla M.D.Chief Medical Officer · born 1973
- Mr. Richard HernandezSenior Vice President of Clinical Development Operations
- Dr. Mark Shilkrut M.D., Ph.D.Senior Vice President of Clinical Development
- Dr. Kamesh Kuchimanchi Ph.D.Senior Vice President of Regulatory Affairs & Quality Assurance
- Dr. Angelos DovletoglouSenior Vice President of CMC & Supply Chain
- Ms. Meghna ChowdarySenior Vice President of Commercial Strategy & Operations